Jan Delabie

Dr. Jan Delabie completed a Residency in Pathology and a PhD in the Departments of Pathology and Genetics at the University of Louvain, Belgium.

In 1993 he became a Research fellow in the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.

He became Assistant Professor of Pathology, University of Leuven in 1995, as well as senior consultant hematopathologist and director of the Laboratory for Molecular Pathology, Department of Pathology, University of Louvain, Belgium

He has been a Senior consultant hematopathologist in the Departments of Pathology at Free University of Brussels, Belgium, and The Norwegian Radium Hospital, Oslo, Norway, becoming the Vice-chairman, The Department of Pathology, The Norwegian Radium Hospital in 2000.

In 2005 Dr. Delabie became Chair of Haematopathology, University Hospital of Oslo, and in 2006 full professor at the University of Oslo, Oslo, Norway.

He joined the Laboratory Medicine Program, University Health Network, Toronto, Ontario, Canada as Senior consultant hematopathologist in 2013, as well as full professor in the Department of Laboratory Medicine & Pathobiololgy at the University of Toronto.

Research Synopsis

Lymphoma research interests

1. diagnostics, biology and immunology of lymphoma
2. pathology review for trials 

Current research projects

1. diffuse large B-cell lymphoma
2. cold agglutinin disease     

Select Publications

Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt  N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle  A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI, Hartmann E, Rosenwald A, Ott G, Muller-Hermelink HK, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, Staudt LM; Lymphoma/Leukemia Molecular Profiling Project. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008 Nov 27;359(22):2313-23.

Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, Sng I, Vose J, Armitage JO, Liang R; International Peripheral T-Cell Lymphoma Project. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood. 2009 Apr 23;113(17):3931-7.

Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, Carty S, Lam LT,  Shaffer AL, Xiao W, Powell J, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Campo E, Jaffe ES, Delabie J, Smeland EB, Rimsza LM, Fisher RI, Weisenburger DD, Chan WC, Staudt LM. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13520-5.

Salaverria I, Zettl A, Beà S, Hartmann EM, Dave SS, Wright GW, Boerma EJ, Kluin PM, Ott G, Chan WC, Weisenburger DD, Lopez-Guillermo A, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Jaffe ES, Staudt LM, Müller-Hermelink HK, Campo E, Rosenwald A; Leukemia and Lymphoma Molecular Profiling Project (LLMPP). Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma. Haematologica. 2008 Sep;93(9):1327-34.

Bassarova A, Tierens A, Lauritzsen GF, Fosså A, Delabie J. Mantle cell lymphoma with partial involvement of the mantle zone: an early infiltration pattern of mantle cell lymphoma? Virchows Arch. 2008 Oct;453(4):407-11.

Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, Eriksson M, Nordström M, Kimby E, Boesen AM, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Akerman M, Ehinger M, Sundström C, Langholm R, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E; Nordic Lymphoma Group. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008 Oct 1;112(7):2687-93.

Young KH, Leroy K, Møller MB, Colleoni GW, Sánchez-Beato M, Kerbauy FR, Haioun C, Eickhoff JC, Young AH, Gaulard P, Piris MA, Oberley TD, Rehrauer WM, Kahl BS, Malter JS, Campo E, Delabie J, Gascoyne RD, Rosenwald A, Rimsza L, Huang J, Braziel RM, Jaffe ES, Wilson WH, Staudt LM, Vose JM, Chan WC, Weisenburger DD, Greiner TC. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood. 2008 Oct 15;112(8):3088-98.

Trøen G, Wlodarska I, Warsame A, Hernández Llodrà S, De Wolf-Peeters C, Delabie J. NOTCH2 mutations in marginal zone lymphoma. Haematologica. 2008 Jul;93(7):1107-9.

Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, Rimsza L, Pileri SA, Chhanabhai M, Gascoyne RD, Armitage JO, Weisenburger DD; International Peripheral T-Cell Lymphoma Project. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral  T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008 Jun 15;111(12):5496-504.                        

Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, Dave SS, Zhao H, Xu W, Rosenwald A, Ott G, Muller Hermelink HK, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Chan WC, Staudt LM. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 2008  Mar 21;319(5870):1676-9.